Simplicity with linagliptin: Efficacy and safety in a broad range of patients with type 2 diabetes mellitus including those with cardiovascular and kidney diseases

At a recent webinar jointly organised by the Malaysian Medical Association and Boehringer Ingelheim celebrating a decade-long of linagliptin use in patients with type 2 diabetes mellitus (T2DM), two distinguished speakers addressed the efficacy and safety of linagliptin in a broad range of patients with T2DM; updates from recent clinical trials and real-world evidence were discussed.